Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Domino's Pizza, Inc. (DPZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Domino's Pizza, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Domino's Pizza, Inc. trades at $357.34 (market cap $11.51B). The key difference: Domino's Pizza, Inc. is the larger of the two by market cap, and Domino's Pizza, Inc. pays a 2.29% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | DPZ | |
|---|---|---|
Market Cap | $9.39B | $11.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $467.30 |
52-Week Low | $241.71 | $282.89 |
Enterprise Value | $9.14B | $16.47B |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
DPZ trades at $350.95, down 2.09% on the day, with a bullish technical signal supported by moving averages and ADX. The company reported Q2 2026 EPS of $4.07, missing estimates, but revenue growth remains steady, with 2025 revenue at $4.94B and net income of $601.70M. Recent news highlights Domino's beta testing a new website and app with customer incentives, while institutional positions show mixed adjustments.
The outlook is mixed: analyst consensus is a Moderate Buy with a $371.67 price target, implying upside, but near-term risks include weaker ticket trends, margin pressure from rising costs, and consecutive EPS misses. High debt levels and insider selling add caution, though operational cash flow strength and brand initiatives support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →
